

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 04/20/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/677,551	10/02/2003	Michael Robert Barbachyn	01337.US1	9537
25533	7590 04/20/2006		EXAMINER	
PHARMACIA & UPJOHN			HABTE, k	CAHSAY
7000 Portage Road KZO-300-104		ART UNIT	PAPER NUMBER	
KALAMAZOO, MI 49001			1624	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
•	10/677,551	BARBACHYN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Kahsay Habte	1624			
The MAILING DATE of this communication app		orrespondence address			
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1)⊠ Responsive to communication(s) filed on <u>08 December 2005</u> .					
2a) This action is <b>FINAL</b> . 2b) ⊠ This	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.				
3)☐ Since this application is in condition for allowar	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) <u>2-8,11-18,20-23 and 26-36</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) Claim(s) 2-8,11-18,20-23 and 26-36 is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	r election requirement.				
Application Papers					
9) The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.					
	·	•			
Attachment(s)		*			
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail D	ate Patent Application (PTO-152)			
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 12/08/2005.	6) Other:				

# **DETAILED ACTION**

1. Claims 2-8, 11-18, 20-23 and 26-36 are pending in this application.

## Continued Examination Under 37 CFR 1.114

2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 12/08/2005 has been entered. The reference submitted with the IDS does not raise the issue of patentability.

Upon further review of the case, it is deemed necessary to raise minor issues that need further rejection.

#### Information Disclosure Statement

3. Applicant's Information Disclosure Statement, filed on 12/08/2005 has been acknowledged. Please refer to Applicant's copies of the 1449 submitted herewith. Note that the 1449 submitted on 11/21/2005 is a duplicate of the 1449 submitted on 12/08/2005.

Application/Control Number: 10/677,551

Art Unit: 1624

# Claim Rejections - 35 USC § 112

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 2-8, 11-18, 20-23 and 26-36 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention:

- a. In claim 20 (page 14), the phrase "each  $R^{15}$  is independently .. (c) Oxo" is incorrect. An "Oxo" substituent is divalent radical represented by =O, thus, it is not permitted to be a substituent for variable X is  $C(R^{15})_2$ -O- $C(R^{15})_2$ -".
- b. Claims 17-18 and 30 are rejected because said claims are improperly dependent on claim 20. The species in claims 17 and 30 and most of the species in claim 18 are spiro compounds i.e. R<sup>1</sup> and R<sup>2</sup> together with the carbon atom to which they are attached form a pyrimidine-trione or indene derivative, but claim 20 does not permit this. Note that there is no definition in claim 20 that defines R<sup>1</sup> and R<sup>2</sup> as forming a spiro ring with the tricyclic ring.
- c. Claim 31 is rejected because it is improperly dependent from claim 20. Claim 31 depends from claim 20, but there is no proviso in claim 20. This proviso was originally presented in deleted claim 1.

Application/Control Number: 10/677,551 Page 4

Art Unit: 1624

d. In claim 14, the phrase "R<sup>15</sup> is independently.. (c) Oxo" is also incorrect.

Since the morpholine portion of the ring carbon has already hydrogen attached to it, R<sup>15</sup> can't be an oxo group. It is recommended that applicants fix any similar problems through out the claims.

### Conclusion

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (571) 272-0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Wilson can be reached at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571)-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1624

Kahsay Habte, Primary Examiner Art Unit 1624

KH

April 13, 2006